Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7)

Elsevier

Available online 23 February 2022, 101601

Seminars in ImmunologyHighlights•

Resolution of inflammation is an active process mediated by molecules usually referred to as pro-resolving mediators.

AnxA1 and Ang-(1-7) have been shown to decrease the severity of tissue damage in various models of infection.

These molecules decrease inflammation while maintaining or enhancing the ability of the host to deal with infection.

There is potential for translating preclinical data with AnxA1 and Ang-(1-7) to patients with various infectious diseases.

Abstract

Infectious diseases, once believed to be an eradicable public health threat, still represent a leading cause of death worldwide. Environmental and social changes continuously favor the emergence of new pathogens and rapid dissemination around the world. The limited availability of anti-viral therapies and increased antibiotic resistance has made the therapeutic management of infectious disease a major challenge. Inflammation is a primordial defense to protect the host against invading microorganisms. However, dysfunctional inflammatory responses contribute to disease severity and mortality during infections. In recent years, a few studies have examined the relevance of resolution of inflammation in the context of infections. Inflammation resolution is an active integrated process transduced by several pro-resolving mediators, including Annexin A1 and Angiotensin-(1-7). Here, we examine some of the cellular and molecular circuits triggered by pro-resolving molecules and that may be beneficial in the context of infectious diseases.

Keywords

Infection

Resolution pharmacology

Angiotensin-(1-7)

Annexin A1

Virus

Bacteria

View full text

© 2022 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif